Arbutus Biopharma (I9DN) Stock Overview
A clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
I9DN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Arbutus Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.13 |
| 52 Week High | US$4.31 |
| 52 Week Low | US$2.55 |
| Beta | 0.66 |
| 1 Month Change | 5.73% |
| 3 Month Change | 13.76% |
| 1 Year Change | 25.42% |
| 3 Year Change | 86.30% |
| 5 Year Change | 22.05% |
| Change since IPO | -1.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| I9DN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.2% | -0.8% | -0.07% |
| 1Y | 25.4% | -32.9% | 11.6% |
Return vs Industry: I9DN exceeded the German Biotechs industry which returned -33.1% over the past year.
Return vs Market: I9DN exceeded the German Market which returned 11.6% over the past year.
Price Volatility
| I9DN volatility | |
|---|---|
| I9DN Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: I9DN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: I9DN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 44 | Lindsay Androski | www.arbutusbio.com |
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology.
Arbutus Biopharma Corporation Fundamentals Summary
| I9DN fundamental statistics | |
|---|---|
| Market cap | €809.96m |
| Earnings (TTM) | -€35.97m |
| Revenue (TTM) | €12.43m |
Is I9DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I9DN income statement (TTM) | |
|---|---|
| Revenue | US$14.61m |
| Cost of Revenue | US$29.05m |
| Gross Profit | -US$14.44m |
| Other Expenses | US$27.84m |
| Earnings | -US$42.28m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.22 |
| Gross Margin | -98.86% |
| Net Profit Margin | -289.45% |
| Debt/Equity Ratio | 4.8% |
How did I9DN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/16 10:58 |
| End of Day Share Price | 2025/12/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arbutus Biopharma Corporation is covered by 19 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Martin | Bloom Burton & Co. |
| Madhu Kumar | B. Riley Securities, Inc. |
| Douglas Loe | Cantor Fitzgerald Canada Corporation |